Semaglutide treatment in MOSH is associated with altered DNA methylation patterns of genes related to glycolipid metabolism.
Semaglutide isn’t just moving numbers on the scale. New data shows this research peptide may be tweaking DNA itself—at least in the context of male obesity-associated secondary hypogonadism (MOSH). Researchers in China dug into how semaglutide alters the epigenetic landscape, specifically DNA methylation and miRNA expression, in MOSH patients. The result: clear shifts in gene regulation tied to glycolipid metabolism.
Sci Rep
by Guo Y, Su J, Shen L et al.
“Semaglutide treatment in MOSH is associated with altered DNA methylation patterns of genes related to glycolipid metabolism. Guo Y(1), Su J(1), Shen L(1), Ding C(1), Wen Y(1), Li Z(1), Li F(2). Author information: (1)Department of endocrinology, The seventh affiliated hospital, Sun Yat-sen University, No. 628, Zhenyuan Road, Xinhu Street, Guangming District, Shenzhen, 518107, Guangdong, China. (2)Department of endocrinology, The seventh affiliated hospital, Sun Yat-sen University, No. 628, Zhenyuan Road, Xinhu Street, Guangming District, Shenzhen, 518107, Guangdong, China. 472655037@qq.com. Male obesity-associated secondary hypogonadism(MOSH) is a common disease among severely obese male patients. Although surgical interventions have demonstrated clinical benefits, a subset of patients continue to experience MOSH following surgery. Therefore, this study aims to investigate epigenetic changes associated with the use of the weight-loss drug Semaglutide in MOSH, focusing on DNA methylation and miRNA expression. In this exploratory study, samples were classified into three groups: a control group (n = 2), a MOSH group (n = 7), and a follow-up group (n = 4). DNA methylation analysis was performed on all samples, while miRNA sequencing was conducted on a subset of the samples: 2 from the control group, 7 from the MOSH group, and 2 from the follow-up group. Differentially expressed miRNAs (DEMs) were analyzed through the R package "limma", and the methylation level of CpG sites was analyzed based on the methylation β value, obtaining differentially methylated genes (DMGs). The functional enrichment analysis of miRNA target genes and methylation change genes was conducted using the R package "clusterProfiler". Finally, the regulatory networks of miRNA and methylation genes as well as the protein-protein interaction (PPI) network were analyzed. A total of 6 DEMs were screened out. The target genes of these DEMs were mainly enriched in pathways such as ATP binding, phosphorylation, cell adhesion, and Glycosphingolipid biosynthesis. Eighty DMGs were identified, and the largest number of DMGs were found in the X chromosome. In the regulatory network of DMGs and DEMs, hsa-miR-423-5p regulates most of these DMGs. Moreover, the PPI network shows that DPP6, DPP10, CACNA1C, and CNTNAP2 are the proteins with the strongest connectivity. Notably, differential CpG methylation changes were observed on chromosome 7, indicating a potential region of epigenetic alteration in MOSH; however, the biological and functional relevance of these changes remains unclear. Collectively, these findings suggest that Semaglutide treatment in MOSH may be associated with concurrent alterations in DNA methylation and miRNA expression, implicating genes related to energy and glycolipid metabolism, including DPP6, DPP10, CACNA1C, and CNTNAP2. These results are exploratory and hypothesis-generating, providing preliminary observations to inform future validation studies. © 2026. The Author(s). Conflict of interest statement: Declarations. Competing interests: The authors declare no competing interests.”
Let’s cut through the jargon. The study split samples into three groups: healthy controls, MOSH patients, and a follow-up group after semaglutide treatment. Using DNA methylation analysis and miRNA sequencing, the team mapped out which genes and regulatory RNAs changed with peptide intervention.
Key findings:
6 differentially expressed miRNAs popped up, many targeting genes linked to ATP binding, phosphorylation, cell adhesion, and glycosphingolipid biosynthesis.
80 genes showed new methylation patterns after semaglutide, with the X chromosome showing the most action.
The miRNA hsa-miR-423-5p emerged as a major regulator, influencing a large chunk of these target genes.
Proteins DPP6, DPP10, CACNA1C, and CNTNAP2 stood out in the protein-protein interaction network—heavy hitters in energy and glycolipid pathways.
Distinct methylation changes appeared on chromosome 7, hinting at a new epigenetic hotspot in MOSH.
What does this mean for the research community? Semaglutide is doing more than just shifting metabolic endpoints—it’s potentially rewiring the way genes tied to energy and lipid handling are expressed. These findings are early, but they raise big questions about how peptide interventions might drive deeper biological change.
Want the nitty gritty on semaglutide’s research profile? Check out the semaglutide page. For those sourcing compounds, the vendor directory is your next stop. Peptide research is nowhere near done surprising us.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.